Compare · COR vs MCK
COR vs MCK
Side-by-side comparison of Cencora Inc. (COR) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $93.24B, about 1.7x COR ($53.51B).
- Over the past year, COR is down 3.2% and MCK is up 9.6% - MCK leads by 12.8 points.
- MCK has been more active in the news (34 items in the past 4 weeks vs 5 for COR).
- Both have 25 recent analyst ratings on file.
- Company
- Cencora Inc.
- McKesson Corporation
- Price
- $275.05+1.77%
- $775.79+2.51%
- Market cap
- $53.51B
- $93.24B
- 1M return
- +8.86%
- +4.39%
- 1Y return
- -3.15%
- +9.63%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 34
- Recent ratings
- 25
- 25
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest COR
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SD filed by Cencora Inc.
- Director Durcan Dermot Mark bought $1,065,040 worth of shares (4,000 units at $266.26), increasing direct ownership by 17% to 27,767 units (SEC Form 4)
- Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
- Cencora Announces Updated Fiscal Year 2026 Financial Outlook
- SEC Form 10-Q filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Reports Fiscal 2026 Second Quarter Results
- Director Tyler Lauren M was granted 99 shares, increasing direct ownership by 3% to 3,809 units (SEC Form 4)
- Director Cooper Ellen was granted 99 shares, increasing direct ownership by 14% to 796 units (SEC Form 4)
Latest MCK
- EVP, Chief Strategy & BDO Rodgers Thomas L sold $604,420 worth of shares (822 units at $735.30) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,268 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B sold $1,331,255 worth of shares (1,810 units at $735.50) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 4,798 units (SEC Form 4)
- McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
- SEC Form 4 filed by EVP & CFO Cheung Kenny K
- SEC Form 3 filed by new insider Cheung Kenny K
- SEC Form SD filed by McKesson Corporation
- EVP and Chief Legal Officer Lau Michele sold $2,701,870 worth of shares (3,550 units at $761.09) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 3,247 units (SEC Form 4)
- EVP & CFO Vitalone Britt J. converted options into 1,476 shares and covered exercise/tax liability with 581 shares, increasing direct ownership by 4% to 21,953 units (SEC Form 4)
- Chief Executive Officer Tyler Brian S. converted options into 4,579 shares and covered exercise/tax liability with 1,831 shares, increasing direct ownership by 11% to 27,774 units (SEC Form 4)
- EVP & Chief HR Officer Smith Leann B converted options into 679 shares and covered exercise/tax liability with 268 shares, increasing direct ownership by 7% to 6,608 units (SEC Form 4)